LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Enhanced PAtient Clinical Streamlining (EPACS): Quality Initiative to Improve Healthcare for New Surgical Outpatient Visits.

    Vos, Elvira L / Cho, Jessica S / Schmeltz, Joseph / Teri, Nick / Law, Ethel B / Paisley, Kathleen / Begue, Aaron / Loumeau, Helen / Suozzo, Sherri H / Anderson-Dunkley, Latasha / Gardner, Ginger J / Jewell, Elizabeth / Singer, Samuel / Abu-Rustum, Nadeem / Jarnagin, William R / Aguilar, Julio Garcia / Drebin, Jeffrey / Strong, Vivian E

    Annals of surgical oncology

    2022  Volume 29, Issue 3, Page(s) 1789–1796

    Abstract: Purpose: For patients who select a specialty hospital for cancer treatment, the wait time until the initial consultation leaves patients anxious and delays treatment. To improve quality of care, we implemented an enhanced patient clinical streamlining ( ... ...

    Abstract Purpose: For patients who select a specialty hospital for cancer treatment, the wait time until the initial consultation leaves patients anxious and delays treatment. To improve quality of care, we implemented an enhanced patient clinical streamlining (EPACS) process that establishes an early connection and coordinates care before the first surgical outpatient visit at our specialty cancer center.
    Methods: During a pre-visit EPACS phone call to new patients, an advanced practice provider (APP) collected medical history and ordered work-up tests or consultations if feasible. First visit cancellation rate, number of patients who started treatment, time to start of treatment, and satisfaction by the care team and patient were compared between patients treated with versus without EPACS.
    Results: Among 5062 consecutive new patients, 720 (14%) received an EPACS call and 4342 did not (86%); work-up was ordered pre-visit in 34% and 16%, respectively. Fewer EPACS patients cancelled the first visit (4.6% vs. 12%, p < 0.001), more started treatment (55% vs. 50%, p = 0.037), and their time to treatment was shorter, but not significantly (median 17 vs. 19 days, p = 0.086). Patient interaction was considered to be improved by EPACS by 17 of 17 APPs and 14 of 16 surgeons, and outpatient clinic efficiency by 14 of 17 APPs and 13 of 16 surgeons. EPACS reduced anxiety and increased preparedness for the first visit in 29 of 31 patients.
    Conclusions: EPACS improved effectiveness, timeliness, and physician and patient satisfaction with health care at our cancer center.
    MeSH term(s) Ambulatory Care Facilities ; Humans ; Outpatients ; Patient Satisfaction ; Physicians ; Referral and Consultation
    Language English
    Publishing date 2022-01-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1200469-8
    ISSN 1534-4681 ; 1068-9265
    ISSN (online) 1534-4681
    ISSN 1068-9265
    DOI 10.1245/s10434-021-11126-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4042: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.

    Cavnar, Michael J / Wang, Lin / Balachandran, Vinod P / Antonescu, Cristina R / Tap, William D / Keohan, Mary / Singer, Sam / Temple, Larissa / Nash, Garrett M / Weiser, Martin R / Guillem, Jose G / Aguilar, Julio Garcia / DeMatteo, Ronald P / Paty, Philip B

    Annals of surgical oncology

    2017  Volume 24, Issue 13, Page(s) 3972–3980

    Abstract: Background: Approximately 5% of gastrointestinal stromal tumors (GISTs) originate in the rectum, and historically, radical resection was commonly performed. Little is known about the outcome for rectal GIST in the era of imatinib.: Methods: Using a ... ...

    Abstract Background: Approximately 5% of gastrointestinal stromal tumors (GISTs) originate in the rectum, and historically, radical resection was commonly performed. Little is known about the outcome for rectal GIST in the era of imatinib.
    Methods: Using a prospectively maintained database, this study retrospectively analyzed 47 localized primary rectal GISTs treated at our center from 1982 to 2016, stratified by when imatinib became available in 2000. Overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) were analyzed by the Kaplan-Meier method.
    Results: Rectal GISTs represented 7.1% of 663 primary GISTs. The findings showed 17 patients in the pre-imatinib era and 30 patients in the imatinib era. The two groups had similar follow-up evaluation, age, gender, Miettinen risk, and distance to the anal verge. In the imatinib era, tumors were smaller at diagnosis (median 4 vs. 5 cm; p = 0.029), and 24 of the 30 patients received perioperative imatinib. In the high-risk patients, organ preservation and negative margins were more common among the 13 patients treated with neoadjuvant imatinib than among the 21 patients treated directly with surgery. High-risk patients who received perioperative imatinib (n = 15) had greater (or nearly significantly greater) 5-year OS, DSS, local RFS, and distant RFS than those who did not (n = 19) (91, 100, 100, and 71% vs. 47, 65, 74, and 41%; p = 0.049, 0.052, 0.077, 0.051, respectively). In the imatinib era, no patient has had a local recurrence or death due to GIST.
    Conclusions: The use of imatinib is associated with organ preservation and improved oncologic outcome for patients with rectal GIST.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/therapeutic use ; Female ; Follow-Up Studies ; Gastrointestinal Neoplasms/drug therapy ; Gastrointestinal Neoplasms/mortality ; Gastrointestinal Neoplasms/pathology ; Gastrointestinal Stromal Tumors/drug therapy ; Gastrointestinal Stromal Tumors/mortality ; Gastrointestinal Stromal Tumors/pathology ; Humans ; Imatinib Mesylate/therapeutic use ; Male ; Medical Oncology ; Middle Aged ; Neoadjuvant Therapy/mortality ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Organ Preservation ; Prognosis ; Prospective Studies ; Rectal Neoplasms/drug therapy ; Rectal Neoplasms/mortality ; Rectal Neoplasms/pathology ; Retrospective Studies ; Survival Rate
    Chemical Substances Antineoplastic Agents ; Imatinib Mesylate (8A1O1M485B)
    Language English
    Publishing date 2017-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1200469-8
    ISSN 1534-4681 ; 1068-9265
    ISSN (online) 1534-4681
    ISSN 1068-9265
    DOI 10.1245/s10434-017-6087-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4042: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers.

    Cercek, Andrea / Chatila, Walid K / Yaeger, Rona / Walch, Henry / Fernandes, Gustavo Dos Santos / Krishnan, Asha / Palmaira, Lerie / Maio, Anna / Kemel, Yelena / Srinivasan, Preethi / Bandlamudi, Chaitanya / Salo-Mullen, Erin / Tejada, Prince R / Belanfanti, Kimeisha / Galle, Jesse / Joseph, Vijai / Segal, Neil / Varghese, Anna / Reidy-Lagunes, Diane /
    Shia, Jinru / Vakiani, Efsevia / Mondaca, Sebastian / Mendelsohn, Robin / Lumish, Melissa A / Steinruecke, Felix / Kemeny, Nancy / Connell, Louise / Ganesh, Karuna / Markowitz, Arnold / Nash, Garrett / Guillem, Jose / Smith, J Joshua / Paty, Phillip B / Zhang, Liying / Mandelker, Diana / Birsoy, Ozge / Robson, Mark / Offit, Kenneth / Taylor, Barry / Berger, Michael / Solit, David / Weiser, Martin / Saltz, Leonard B / Aguilar, Julio Garcia / Schultz, Nikolaus / Diaz, Luis A / Stadler, Zsofia K

    Journal of the National Cancer Institute

    2021  Volume 113, Issue 12, Page(s) 1683–1692

    Abstract: Background: The causative factors for the recent increase in early-onset colorectal cancer (EO-CRC) incidence are unknown. We sought to determine if early-onset disease is clinically or genomically distinct from average-onset colorectal cancer (AO-CRC).! ...

    Abstract Background: The causative factors for the recent increase in early-onset colorectal cancer (EO-CRC) incidence are unknown. We sought to determine if early-onset disease is clinically or genomically distinct from average-onset colorectal cancer (AO-CRC).
    Methods: Clinical, histopathologic, and genomic characteristics of EO-CRC patients (2014-2019), divided into age 35 years and younger and 36-49 years at diagnosis, were compared with AO-CRC (50 years and older). Patients with mismatch repair deficient tumors, CRC-related hereditary syndromes, and inflammatory bowel disease were excluded from all but the germline analysis. All statistical tests were 2-sided.
    Results: In total, 759 patients with EO-CRC (35 years, n = 151; 36-49 years, n = 608) and AO-CRC (n = 687) were included. Left-sided tumors (35 years and younger = 80.8%; 36-49 years = 83.7%; AO = 63.9%; P < .001 for both comparisons), rectal bleeding (35 years and younger = 41.1%; 36-49 years = 41.0%; AO = 25.9%; P = .001 and P < .001, respectively), and abdominal pain (35 years and younger = 37.1%; 36-49 years = 34.0%; AO = 26.8%; P = .01 and P = .005, respectively) were more common in EO-CRC. Among microsatellite stable tumors, we found no differences in histopathologic tumor characteristics. Initially, differences in TP53 and Receptor Tyrosine Kinase signaling pathway (RTK-RAS)alterations were noted by age. However, on multivariate analysis including somatic gene analysis and tumor sidedness, no statistically significant differences at the gene or pathway level were demonstrated. Among advanced microsatellite stable CRCs, chemotherapy response and survival were equivalent by age cohorts. Pathogenic germline variants were identified in 23.3% of patients 35 years and younger vs 14.1% of AO-CRC (P = .01).
    Conclusions: EO-CRCs are more commonly left-sided and present with rectal bleeding and abdominal pain but are otherwise clinically and genomically indistinguishable from AO-CRCs. Aggressive treatment regimens based solely on the age at CRC diagnosis are not warranted.
    MeSH term(s) Adult ; Humans ; Abdominal Pain/genetics ; Colorectal Neoplasms/diagnosis ; Colorectal Neoplasms/epidemiology ; Colorectal Neoplasms/genetics ; Genetic Testing ; Incidence
    Language English
    Publishing date 2021-08-18
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2992-0
    ISSN 1460-2105 ; 0027-8874 ; 0198-0157
    ISSN (online) 1460-2105
    ISSN 0027-8874 ; 0198-0157
    DOI 10.1093/jnci/djab124
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.131: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Clinical and genetic determinants of ovarian metastases from colorectal cancer.

    Ganesh, Karuna / Shah, Ronak H / Vakiani, Efsevia / Nash, Garrett M / Skottowe, Hugh P / Yaeger, Rona / Cercek, Andrea / Lincoln, Anne / Tran, Christina / Segal, Neil H / Reidy, Diane L / Varghese, Anna / Epstein, Andrew S / Sonoda, Yukio / Chi, Dennis / Guillem, Jose / Temple, Larissa / Paty, Philip / Hechtman, Jaclyn /
    Shia, Jinru / Weiser, Martin / Aguilar, Julio Garcia / Kemeny, Nancy / Berger, Michael F / Saltz, Leonard / Stadler, Zsofia K

    Cancer

    2016  Volume 123, Issue 7, Page(s) 1134–1143

    Abstract: Background: Ovarian metastases from colorectal cancer (OM-CRC) often are unresponsive to chemotherapy and are associated with poor survival. To the authors' knowledge, the clinicopathologic and genomic predictors of OM-CRC are poorly characterized and ... ...

    Abstract Background: Ovarian metastases from colorectal cancer (OM-CRC) often are unresponsive to chemotherapy and are associated with poor survival. To the authors' knowledge, the clinicopathologic and genomic predictors of OM-CRC are poorly characterized and optimal clinical management remains unclear.
    Methods: Women with a histopathological diagnosis of OM-CRC who were treated at Memorial Sloan Kettering Cancer Center from 1999 to 2015 were identified. Next-generation somatic mutation profiling (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]) was performed on 38 OM-CRC cases, including 21 matched tumor pairs/trios. Regression models were used to analyze variables associated with progression-free survival and overall survival (OS).
    Results: Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS), SMAD family member 4 (SMAD4), and neurotrophic receptor tyrosine kinase 1 (NTRK1) mutations were more frequent in cases of OM-CRC than in instances of CRC occurring without OM. SMAD4 and lysine methyltransferase 2D (KMT2D) mutations were associated with reduced OS. Matched multisite tumor sequencing did not identify OM-specific genomic alterations. Of the 195 patients who underwent oophorectomy for OM-CRC (median age, 49 years with a progression-free survival of 9.4 months and an OS of 23 months from oophorectomy), 76% had extraovarian metastasis (EOM). In multivariable analysis, residual disease after surgery (R2 resection) was associated with worse survival. Patients with EOM were less likely to achieve R0/R1 surgical resection status (complete macroscopic resection without clinical/radiological evidence of disease) (48% vs 94%). However, if R0/R1 resection status was achieved, both patients with (35.9 months vs 12 months) and without (43.2 months vs 14.5 months) EOM were found to have better OS. Among 114 patients with R0/R1 resection status, 23 (20%) had no disease recurrence, including 10 patients (9%) with > 3 years of follow-up.
    Conclusions: Loss-of-function alterations in SMAD4 are frequent and predictive of worse survival in patients with OM-CRC. Similar to oligometastatic CRC to the lung or liver, surgical resection of OM-CRC is associated with a better outcome only if all macroscopic metastatic disease is resected. Cancer 2017;123:1134-1143. © 2016 American Cancer Society.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/mortality ; Colorectal Neoplasms/pathology ; Colorectal Neoplasms/therapy ; Combined Modality Therapy/methods ; Female ; Genetic Predisposition to Disease ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Ovarian Neoplasms/diagnosis ; Ovarian Neoplasms/etiology ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/therapy ; Prognosis ; Proportional Hazards Models ; Proto-Oncogene Proteins p21(ras)/genetics ; Smad4 Protein/genetics ; Treatment Outcome ; Tumor Burden ; Young Adult
    Chemical Substances Biomarkers, Tumor ; Smad4 Protein ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2)
    Language English
    Publishing date 2016-11-22
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 1429-1
    ISSN 1097-0142 ; 0008-543X ; 1934-662X
    ISSN (online) 1097-0142
    ISSN 0008-543X ; 1934-662X
    DOI 10.1002/cncr.30424
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.146: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Risk of Surgical Site Infection (SSI) following Colorectal Resection Is Higher in Patients With Disseminated Cancer: An NCCN Member Cohort Study.

    Kamboj, Mini / Childers, Teresa / Sugalski, Jessica / Antonelli, Donna / Bingener-Casey, Juliane / Cannon, Jamie / Cluff, Karie / Davis, Kimberly A / Dellinger, E Patchen / Dowdy, Sean C / Duncan, Kim / Fedderson, Julie / Glasgow, Robert / Hall, Bruce / Hirsch, Marilyn / Hutter, Matthew / Kimbro, Lisa / Kuvshinoff, Boris / Makary, Martin /
    Morris, Melanie / Nehring, Sharon / Ramamoorthy, Sonia / Scott, Rebekah / Sovel, Mindy / Strong, Vivian / Webster, Ashley / Wick, Elizabeth / Aguilar, Julio Garcia / Carlson, Robert / Sepkowitz, Kent

    Infection control and hospital epidemiology

    2018  Volume 39, Issue 5, Page(s) 555–562

    Abstract: BACKGROUNDSurgical site infections (SSIs) following colorectal surgery (CRS) are among the most common healthcare-associated infections (HAIs). Reduction in colorectal SSI rates is an important goal for surgical quality improvement.OBJECTIVETo examine ... ...

    Abstract BACKGROUNDSurgical site infections (SSIs) following colorectal surgery (CRS) are among the most common healthcare-associated infections (HAIs). Reduction in colorectal SSI rates is an important goal for surgical quality improvement.OBJECTIVETo examine rates of SSI in patients with and without cancer and to identify potential predictors of SSI risk following CRSDESIGNAmerican College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) data files for 2011-2013 from a sample of 12 National Comprehensive Cancer Network (NCCN) member institutions were combined. Pooled SSI rates for colorectal procedures were calculated and risk was evaluated. The independent importance of potential risk factors was assessed using logistic regression.SETTINGMulticenter studyPARTICIPANTSOf 22 invited NCCN centers, 11 participated (50%). Colorectal procedures were selected by principal procedure current procedural technology (CPT) code. Cancer was defined by International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes.MAIN OUTCOMEThe primary outcome of interest was 30-day SSI rate.RESULTSA total of 652 SSIs (11.06%) were reported among 5,893 CRSs. Risk of SSI was similar for patients with and without cancer. Among CRS patients with underlying cancer, disseminated cancer (SSI rate, 17.5%; odds ratio [OR], 1.66; 95% confidence interval [CI], 1.23-2.26; P=.001), ASA score ≥3 (OR, 1.41; 95% CI, 1.09-1.83; P=.001), chronic obstructive pulmonary disease (COPD; OR, 1.6; 95% CI, 1.06-2.53; P=.02), and longer duration of procedure were associated with development of SSI.CONCLUSIONSPatients with disseminated cancer are at a higher risk for developing SSI. ASA score >3, COPD, and longer duration of surgery predict SSI risk. Disseminated cancer should be further evaluated by the Centers for Disease Control and Prevention (CDC) in generating risk-adjusted outcomes.Infect Control Hosp Epidemiol 2018;39:555-562.
    MeSH term(s) Adult ; Aged ; Cohort Studies ; Colorectal Neoplasms/epidemiology ; Colorectal Neoplasms/surgery ; Databases, Factual ; Digestive System Surgical Procedures/adverse effects ; Female ; Humans ; Logistic Models ; Male ; Middle Aged ; Rectum/surgery ; Risk Factors ; Surgical Wound Infection/epidemiology ; Surgical Wound Infection/etiology ; United States/epidemiology
    Language English
    Publishing date 2018-03-19
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 639378-0
    ISSN 1559-6834 ; 0195-9417 ; 0899-823X
    ISSN (online) 1559-6834
    ISSN 0195-9417 ; 0899-823X
    DOI 10.1017/ice.2018.40
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1714: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.

    Latham, Alicia / Srinivasan, Preethi / Kemel, Yelena / Shia, Jinru / Bandlamudi, Chaitanya / Mandelker, Diana / Middha, Sumit / Hechtman, Jaclyn / Zehir, Ahmet / Dubard-Gault, Marianne / Tran, Christina / Stewart, Carolyn / Sheehan, Margaret / Penson, Alexander / DeLair, Deborah / Yaeger, Rona / Vijai, Joseph / Mukherjee, Semanti / Galle, Jesse /
    Dickson, Mark A / Janjigian, Yelena / O'Reilly, Eileen M / Segal, Neil / Saltz, Leonard B / Reidy-Lagunes, Diane / Varghese, Anna M / Bajorin, Dean / Carlo, Maria I / Cadoo, Karen / Walsh, Michael F / Weiser, Martin / Aguilar, Julio Garcia / Klimstra, David S / Diaz, Luis A / Baselga, Jose / Zhang, Liying / Ladanyi, Marc / Hyman, David M / Solit, David B / Robson, Mark E / Taylor, Barry S / Offit, Kenneth / Berger, Michael F / Stadler, Zsofia K

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2018  Volume 37, Issue 4, Page(s) 286–295

    Abstract: Purpose: Microsatellite instability (MSI) and/or mismatch repair deficiency (MMR-D) testing has traditionally been performed in patients with colorectal (CRC) and endometrial cancer (EC) to screen for Lynch syndrome (LS)-associated cancer predisposition. ...

    Abstract Purpose: Microsatellite instability (MSI) and/or mismatch repair deficiency (MMR-D) testing has traditionally been performed in patients with colorectal (CRC) and endometrial cancer (EC) to screen for Lynch syndrome (LS)-associated cancer predisposition. The recent success of immunotherapy in high-frequency MSI (MSI-H) and/or MMR-D tumors now supports testing for MSI in all advanced solid tumors. The extent to which LS accounts for MSI-H across heterogeneous tumor types is unknown. Here, we establish the prevalence of LS across solid tumors according to MSI status.
    Methods: MSI status was determined using targeted next-generation sequencing, with tumors classified as MSI-H, MSI-indeterminate, or microsatellite-stable. Matched germline DNA was analyzed for mutations in LS-associated mismatch repair genes ( MLH1, MSH2, MSH6, PMS2, EPCAM). In patients with LS with MSI-H/I tumors, immunohistochemical staining for MMR-D was assessed.
    Results: Among 15,045 unique patients (more than 50 cancer types), LS was identified in 16.3% (53 of 326), 1.9% (13 of 699), and 0.3% (37 of 14,020) of patients with MSI-H, MSI-indeterminate, and microsatellite-stable tumors, respectively ( P < .001). Among patients with LS with MSI-H/I tumors, 50% (33 of 66) had tumors other than CRC/EC, including urothelial, prostate, pancreas, adrenocortical, small bowel, sarcoma, mesothelioma, melanoma, gastric, and germ cell tumors. In these patients with non-CRC/EC tumors, 45% (15 of 33) did not meet LS genetic testing criteria on the basis of personal/family history. Immunohistochemical staining of LS-positive MSI-H/I tumors demonstrated MMR-D in 98.2% (56 of 57) of available cases.
    Conclusion: MSI-H/MMR-D is predictive of LS across a much broader tumor spectrum than currently appreciated. Given implications for cancer surveillance and prevention measures in affected families, these data support germline genetic assessment for LS for patients with an MSI-H/MMR-D tumor, regardless of cancer type or family cancer history.
    MeSH term(s) Biomarkers, Tumor/genetics ; Colorectal Neoplasms, Hereditary Nonpolyposis/epidemiology ; Colorectal Neoplasms, Hereditary Nonpolyposis/genetics ; Colorectal Neoplasms, Hereditary Nonpolyposis/pathology ; DNA Mismatch Repair ; Female ; Genetic Predisposition to Disease ; Humans ; Male ; Microsatellite Instability ; Middle Aged ; Mutation ; New York City/epidemiology ; Phenotype ; Prevalence ; Prospective Studies ; Transcriptome
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2018-10-30
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.18.00283
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top